Results 31 to 40 of about 1,247,684 (370)
Epidemiology of Prostate Cancer
World Journal of Oncology, 2019 Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indolent course that may require only active surveillance ...
Prashanth Rawla
semanticscholar +1 more source
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network, 2019 The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate
J. Mohler +32 more
semanticscholar +1 more source
3D EAGAN: 3D edge-aware attention generative adversarial network for prostate segmentation in transrectal ultrasound images [PDF]
arXiv, 2023 Automatic prostate segmentation in TRUS images has always been a challenging problem, since prostates in TRUS images have ambiguous boundaries and inhomogeneous intensity distribution. Although many prostate segmentation methods have been proposed, they still need to be improved due to the lack of sensibility to edge information.
arxiv
New England Journal of Medicine, 2004 BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone ...
D. Petrylak +13 more
semanticscholar +1 more source
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
New England Journal of Medicine, 2015 BACKGROUND Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT ...
C. Sweeney +16 more
semanticscholar +1 more source
Annual Review of Medicine, 1975 Several distinct types of prostatitis, or prostatitis syndromes, are now recognized. The most common forms include acute and chronic bacterial prostatitis, nonbacterial prostatitis, and prostatodynia. Bacterial prostatitis, caused mainly by coliform bacteria, Pseudomonas, and Enterococcus faecalis, is often difficult to cure and usually requires ...
openaire +5 more sources
Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer
New England Journal of Medicine, 2017 Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration‐resistant prostate cancer.
K. Fizazi +14 more
semanticscholar +1 more source
Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
Nature Network Boston, 2016 An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to absent AR expression and often have neuroendocrine features.
H. Beltran +18 more
semanticscholar +1 more source
Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis
BJUI Compass, 2023 Background Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. We performed a systematic review and meta‐analysis to evaluate the prevalence of genomic alterations in NEPC and better understand its molecular features to ...
Junru Chen +6 more
doaj +1 more source
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
New England Journal of Medicine, 2014 BACKGROUND The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor.
E. Antonarakis +20 more
semanticscholar +1 more source